Table 3.
Intranasal vaccines are currently undergoing clinical trials. The data is compiled as per information provided in the COVID-19 vaccine tracker and landscape last assessed on September 19, 2021
| Vaccine name | Platform used | Developers | Doses required | Clinical trial |
|---|---|---|---|---|
| DelNS1–2019-nCoV-RBD-OPT1 | Viral vector (Replicating) | University of Hong Kong, Xiamen University, and Beijing Wantai Biological Pharmacy | 2 | Phase 2 |
| COVI-VAC | Live attenuated virus | Codagenix/Serum Institute of India | 1–2 | Phase 1 |
| CIGB-669 | Protein subunit | Center for Genetic Engineering and Biotechnology (CIGB) | 3 | Phase 1/2 |
| AdCOVID | Viral vector (non-replicating) | Altimmune, Inc. | 1-2 | Phase 1 |
| BBV154 | Viral vector (non-replicating) | Bharat Biotech International Limited | 1 | Phase 1 |
| MV-014-212 | Live attenuated virus | Meissa Vaccines, Inc. | 1 | Phase 1 |